Compare NHI & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NHI | EWTX |
|---|---|---|
| Founded | 1991 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.5B |
| IPO Year | 1994 | 2021 |
| Metric | NHI | EWTX |
|---|---|---|
| Price | $71.92 | $34.84 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $87.00 | $39.00 |
| AVG Volume (30 Days) | 381.8K | ★ 1.3M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.81% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.82 | N/A |
| Revenue | ★ $375,628,000.00 | N/A |
| Revenue This Year | $15.44 | N/A |
| Revenue Next Year | $10.01 | N/A |
| P/E Ratio | $87.93 | ★ N/A |
| Revenue Growth | ★ 12.07 | N/A |
| 52 Week Low | $67.94 | $12.31 |
| 52 Week High | $91.38 | $40.77 |
| Indicator | NHI | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.36 | 52.40 |
| Support Level | $67.94 | $28.27 |
| Resistance Level | $77.80 | $40.36 |
| Average True Range (ATR) | 1.85 | 2.21 |
| MACD | 0.18 | -0.20 |
| Stochastic Oscillator | 44.14 | 36.31 |
National Health Investors Inc is a self-managed REIT that owns, leases, operates, and finances the development of senior housing communities and medical facilities. It operates through two segments: Real Estate Investments and Senior Housing Operating Portfolio (SHOP). The Real Estate Investments segment, which generates the majority of revenue, includes real estate leases, mortgages, and other notes receivable related to independent living facilities, assisted living facilities, entrance fee communities, senior living campuses, skilled nursing facilities, and a hospital. The SHOP segment consists of ventures that own and operate independent living facilities. The company's revenues are derived from rental income, interest and other income, and resident fees and services.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.